RxDoctor Payments Data
★ My doctorsLook up a doctor →

Guilherme Attizzani

Cardiovascular Disease · Cleveland, OHNPI 1144621889

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $946,675 of the $1,280,312 with a category attached, or 73.9%. Medtronic accounts for 98.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $277,865 and has fallen 54.4% since, to $126,661 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,280,312in general payments, 2019–2025

Across 1,642 payments — averaging $779.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1.3M
  • Boston Scientific$7K
  • Abbott$4K
  • Ancora Heart, Inc.$3K
  • Edwards Lifesciences$743
  • Novartis$331
  • plus $494 from 13 others
$1,588,273in research payments, 2019–2025

Across 282 payments — averaging $5632.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$909K
  • Boston Scientific$556K
  • Abbott$108K
  • Gentuity, LLC$16K

What the payments were for

  • Consulting fees$79,6566%
  • Speaking & faculty fees$946,67574%
  • Travel & lodging$215,34917%
  • Food & beverage$38,3503%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)1,524$1,265,153
Boston Scientific21$6,550
Abbott42$4,024
Ancora Heart, Inc.10$3,017
Edwards Lifesciences8$743
Novartis17$331
Siemens Medical Solutions USA, Inc.1$94
Gilead3$66
Teleflex LLC3$63
Abiomed2$63
Cordis US CORP.1$31
Pfizer2$28
Cardiovascular Systems Inc.2$27
Alnylam Pharmaceuticals Inc.1$26
Terumo Medical Corporation1$22
Getinge USA Sales, LLC1$21
Cardiva Medical, Inc.1$20
E.r. Squibb & Sons, L.L.C.1$17
Opsens Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,280,312 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio →

Medicare billing

Part B allowed, 2024
$150,722
Medicare patients
246
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Cleveland

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →